Orthofix Names Max Reinhardt President of Global Spine Business

May 23, 2024

Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Max Reinhardt as President of the Global Spine business effective June 10, 2024. Reinhardt will serve on the Executive Leadership Team and be responsible for leading SeaSpine, the Company’s global spine and biologics business.

Max Reinhardt, incoming President of the Orthofix Global Spine business. (Photo: Business Wire)

Max Reinhardt, incoming President of the Orthofix Global Spine business. (Photo: Business Wire)

Reinhardt’s experience spans more than 30 years in MedTech and pharmaceuticals, assuming positions of increasing responsibility at Johnson & Johnson, including serving as Worldwide President, DePuy Synthes Spine, achieving the number two market share position in the competitive spine market. Additionally, Reinhardt served as Vice President, Marketing U.S. Orthopedics, and Global Franchise Leader and Worldwide President of Joint Reconstruction, Sports Medicine and Power Tools. Reinhardt has worked closely with key opinion leaders and launched market-leading biologics and implant solutions in spine surgery, joint replacement, orthopedic trauma and early intervention, supported by a robust technique-based professional education agenda.

“Max brings strong leadership and a proven track record of success to our global spine business,” said Orthofix President and CEO Massimo Calafiore. “He brings a wealth of experience in driving innovation while continually executing focused strategies to drive commercial success. I look forward to the guidance and expertise he will bring to our organization as we continue to accelerate and position Orthofix as one of the leading spine companies in the market.”

Prior to his experience with Johnson & Johnson, Reinhardt had senior leadership positions with Steris and Olympus in Europe. Most recently, Reinhardt served in different leadership roles for Pacira Biosciences, a company focused on providing innovative non-opioid pain management solutions.

“I am delighted to have the opportunity to lead the talented spine team at Orthofix as we continue to innovate and introduce differentiated products and procedurally integrated solutions to the market to solve complex spine problems,” said Reinhardt. “I believe the company has a strong foundation and is well positioned for growth in the years ahead. I look forward to working with our dedicated team members to deliver new product solutions and provide exceptional support for our surgeon customers and their patients.”

Reinhardt earned his undergraduate diploma from Sparsholt College, Hampshire, U.K. and a Master of Science degree from the University of Hull, U.K.

About Orthofix

Orthofix is a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a leading surgical navigation system. Its products are distributed in more than 60 countries worldwide.

The Company is headquartered in Lewisville, Texas, where it conducts general business, product development, medical education and manufacturing, and has primary offices in Carlsbad, CA, with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics. The combined Company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Maidenhead, UK, Munich, Germany, Paris, France and São Paulo, Brazil.

Forward-Looking Statements

This news release may include forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “continue” or other comparable terminology. Orthofix cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Each forward-looking statement contained in this news release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of robust clinical validation; and the risks identified under the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission (SEC) on March 5, 2024. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Orthofix does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.

Media Relations

Denise Landry



Investor Relations

Louisa Smith, Gilmartin Group


Source: Orthofix Medical Inc.